PatientsVille.com Logo

CATARACT and Medication

PatientsVille

CATARACT Symptoms and Causes

A Cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a Cataract or have had Cataract surgery.

A Cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are

  • Blurry vision
  • Colors that seem faded
  • Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights.
  • Not being able to see well at night
  • Double vision
  • Frequent prescription changes in your eye wear

Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay Cataracts.

NIH: National Eye Institute

Check out the latest treatments for CATARACT

CATARACT treatment research studies

Medication clinical trials, surveys and public health registries


Find Drug Side Effect reports



Medication Side Effects


➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I been on effexxor medication almost 2 weeks and i been having a nausea since i start i m desperate don t know what to do

I cannot swallow my pain medication and fluids seem to back up causing a cough, food is difficult to swallow and seems to lodge in my throat

I have very major problems . since taking medication been in the hospital twiced wih different complications ater taking augmentin

Are there any concerns with starting pristiq about 1 month befor cataract surgery??

I forgot. a starting cataract has been diagnosed, too.

I have developed Angular Cheilitis-like symptoms since starting Tobradex (prescribed for post-operative ocular surgery). Earlier I had similar symptoms as reaction to a drug (unknown) prescribed for post-operative cataract surgery. Can you confirm th

I have used Nasonex for over 10 years and have recently been diagnosed with a Cataract at the age of 43. There are no warnings in the packaging and my doctor had no knowledge of this happening. This is so wrong!! Everyon

I recently had a cataract operation at the Jules Stein hospital eye institute, which is associated with UCLA hospital in Westwood wood California. Although the operation was a success, the use of Versed during the operation was a disaster for me. For

I started taking crestor last year - at age 38. my last week trip to my optometrist revealed that I'm suffering from cataract!! I did the research - apparently one of crestor's side effects is the development of cataract.

My father (83 yrs old) underwent Glaucoma and cataract surgery (left eye only ; right eye had acute Glaucoma and was difficult to be improved) on 31st July 2009. As advised, He recently got checked up by another local doctor because of blurred vision

My mother has experienced iris bombe a couple of months after a cataract surgery and it was treated by laser. it was ok at that time, but because of an inflammation comes and goes with some eye drops, the iris appears again and she is advised now by

Their have been studies indicating the use of Fenofibrate to causing eye Cataracts. I am only 55 years of age and had to have cataract surgery on both eyes and have been on Fenofibrate (54mg ) for about 1.5 years. Their is no one else in my family wi

CATARACT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Economic Evaluation of Femtosecond Laser Assisted Cataract Surgery
Condition: Cataract
Interventions: Procedure: Cataract surgery with Phacoemulsification;   Device: Femtosecond laser-assisted Cataract surgery
Outcome Measures: Incremental Cost/effectiveness ratio defined as cost per incremental therapeutic success.;   Quality of life;   Learning curve of the femtosecond laser-assisted Cataract surgery;   Overall costs of Cataract surgery in both arms from the hospital perspective;   Incremental cost - Utility ratio defined as incremental Cost/QALY (Quality Adjusted Life Year) for healthcare insurance in both arms;   No severe intraoperative or postoperative complications;   Best Corrected Visual Acuity of 0 LogMAR;   Refractive error inferior or equal to 0.75 diopter;   Corneal surgically-induced astigmatism inferior or equal to 0.5 diopter and a postoperative change of astigmatism axis inferior or equal to 20°
2 Recruiting Cataract Removal and Alzheimer's Disease
Conditions: Cataracts;   Alzheimer's Disease
Intervention: Procedure: Immediate Cataract Surgery
Outcome Measures: Visual acuity, spatial contrast sensitivity, visual perception and cognition;   Independent function;   Quality of Life;   Retinal Nerve Fiber Layer
3 Recruiting The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser.
Conditions: Nuclear Sclerosis of the Lens;   Posterior Subcapsular Cataract;   Cortical Cataract
Interventions: Procedure: Femtosecond Laser Assisted Cataract Surgery with Catalys Laser;   Procedure: Femtosecond Laser Assisted Cataract Surgery with LenSx Laser
Outcome Measures: Cumulative Dissipated Energy;   Complete Laser Capsulotomy
4 Unknown  Surgical Treatment of Concurrent Cataract and Primary Pterygium
Conditions: Pterygium;   Cataract;   Lenses, Intraocular
Interventions: Procedure: combined pterygium and Cataract operation;   Procedure: pterygium excision followed by Cataract operation
Outcome Measures: final refraction deviation from target;   change of IOL power from pre-pterygium estimated power
5 Not yet recruiting Comparison of Femtosecond Laser Assisted Cataract Surgery to Conventional Phacoemulsification Cataract Surgery
Condition: Cataract
Intervention:
Outcome Measure: endothelial cell density three months after conventional CEIOL or FLACS compared to baseline
6 Recruiting Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Conditions: Macular Edema, Cystoid;   Vision Disorders;   Diabetic Macular Edema;   Cystoid Macular Edema Following Cataract Surgery;   Cataract
Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex);   Procedure: Cataract surgery
Outcome Measures: change in the central macular thickness;   Change in the visual acuity
7 Unknown  Endothelial Cell Loss After Cataract Surgery
Condition: Cataracts
Interventions: Procedure: Standard phacoemulsification;   Procedure: Reduced ultrasound phacoemulsification
Outcome Measure: Corneal endothelial cell loss by specular microscopy after Cataract surgery
8 Not yet recruiting Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus
Condition: Macular Edema Following Cataract Surgery
Interventions: Drug: Trientine Hydrochloride;   Other: For Arm B there is no therapeutic intervention other than standard of care, which is Cataract surgery.
Outcome Measures: The primary analysis will compare retinal thickness measurements by Optical Coherence Tomography (OCT) between subjects undergoing surgery with and without Trientine use.;   Secondary analyses will involve evaluations of visual acuity and fundus photography.
9 Recruiting Immediate Simultaneous Bilateral Cataract Surgery
Condition: Bilateral Cataract
Interventions: Procedure: ISBCS;   Procedure: DSBCS
Outcome Measures: Visual acuity;   Recovery time and number of post-operative visits
10 Recruiting S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000
Conditions: Cataract;   Macular Degeneration
Interventions: Drug: selenium;   Drug: vitamin E;   Drug: vitamin E placebo;   Drug: selenium placebo
Outcome Measures: Visually significant age-related macular degeneration (AMD);   Cataract with best corrected visual-acuity of 20/30;   Advanced AMD;   Cataract extraction
11 Recruiting Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
Condition: Primary Open-angle Glaucoma
Interventions: Device: iStent supra;   Procedure: Cataract surgery
Outcome Measures: ≥ 20% Reduction in Intraocular Pressure (IOP);   Diurnal IOP Reduction from Baseline
12 Recruiting Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Conditions: Cataract;   Retinal Edema;   Inflammation
Interventions: Drug: Prolensa (bromfenac 0.07%);   Drug: Ilevro (nepafenac 0.3%)
Outcome Measures: Treatment of inflammation associated with Cataract surgery;   Visual Acuity
13 Unknown  Effect of Minimising Ultrasound Power to 1% During Cataract Surgery on Corneal Endothelium.
Condition: Cataract
Interventions: Procedure: one percent ultrasound power in CMICS;   Procedure: 40 percent ultrasound power in CMICS
Outcome Measures: change in endothelial cell count from baseline over time;   change in Intraocular pressure from baseline;   visual acuity;   posterior capsular rupture
14 Recruiting Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses and Cataracts Surgery
Condition: Cataract
Intervention: Procedure: Cataract Surgery
Outcome Measure: Patient overall satisfaction post Cataract surgery
15 Recruiting Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery
Condition: Primary Open Angle Glaucoma
Interventions: Device: iStent;   Procedure: Cataract surgery
Outcome Measures: Rate of sight-threatening adverse events;   Other adverse events
16 Unknown  The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment
Conditions: Efficacy;   Complications
Intervention: Procedure: Cataract surgery with phacoemulsification
Outcome Measures: safety and efficacy of Cataract surgery with phacoemulsification under coumadin and antiaggregant treatment;   other complications
17 Unknown  Microincision Versus Smallincision Combined Surgery
Condition: Cataract Extraction
Interventions: Procedure: Combined Micro- Surgery;   Procedure: Combined Small-Surgery
Outcome Measures: Refractive outcome;   measurements of anterior chamber depth (ACD);   intraocular pressure (IOP);   functional outcome
18 Recruiting Pain Expression in the Perioperative Period of Cataract Surgery
Conditions: Cataract;   Surgery;   Eye Pain
Interventions: Procedure: First eye (FE);   Procedure: Second eye (SE);   Drug: Steroids eye drops
Outcome Measure: Post operative pain level
19 Recruiting Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery
Condition: Primary Open-angle Glaucoma
Interventions: Device: iStent inject;   Procedure: Cataract surgery
Outcome Measures: ≥ 20% Reduction in Intraocular Pressure (IOP);   Diurnal IOP Reduction from Baseline
20 Recruiting Safety & Effectiveness Study of the Hydrus Device for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery
Condition: Primary Open Angle Glaucoma
Interventions: Device: Hydrus Aqueous Implant;   Procedure: Cataract surgery
Outcome Measures: Reduction in mean diurnal IOP from baseline at 24 months following medication washout.;   Mean diurnal washed out IOP change from baseline at 24 months compared between treatment and control groups.